

Head office: 301. Aura Biplex, Premium Retail, Premises, 7, S.V.Road Boriwali (west) Mumbai - 400092 E-mail: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com Board Line: +91-22-42221111 / 42221116 (100 line) CIN: L51496MH2008PLC184997

Date: 30/09/2024

SPIL/CS/SE/2024-2025/31

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INEOUTV01015

Sub: Outcome of Board Meeting held on today i.e. Monday, September 30, 2024
Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015

Dear Sir / Madam.

In terms of Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, September 30, 2024, inter-alia, considered and approved the following businesses:

### 1. Sub-division of face value of equity shares of the Company

Sub-division / split of company's 1 (one) equity share having face value of Rs.10/- (Rupees Ten only) each fully paid-up, into 10 (Ten) equity shares of the Company having face value of Re.1/- (Rupee One only) each fully paid-up, subject to the approval of shareholders and such other approvals as may be required.

### 2. Alteration of capital clause of Memorandum of Association

Consequent to the sub-division of the face value of the equity shares of the Company, the alteration of capital clause of Memorandum of Association of the Company, subject to the approval of shareholders of the Company.

### 3. Members' approval through the process of postal ballot

To seek members' approval through the process of postal ballot for the above-said today's board decision and approved the draft notice of Postal Ballot and authorized Director(s) / KMP(s) to issue the same to the concerned. Appointment of Mr. Vishal Manseta, Practicing Company Secretary as Scrutinizer for postal ballot and matters related thereto.

The notice of the postal ballot will be sent to the Stock Exchange and to the members of the Company and will also be available on the Company's website at www.sudarshanpharma.com and on the website of the stock exchange i.e. BSE Limited at www.bseindia.com in course.

Regd.off.: 301, Aura Biplex, Above Kalyan Jewellers, S V Road Boriwali (West), Mumbai - 400092.



Head office: 301.Aura Biplex, Premium Retail, Premises, 7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com

Board Line: + 91-22-42221111 / 42221116 (100 line) CIN: L51496MH2008PLC184997

4. Calendar of events for proposed corporate action of split / sub-division in nominal value of the equity shares

The Board has approved the calendar of events for the proposed Corporate Action of split / sub-division in nominal value of the equity shares of the Company, as detailed in Annexure-I enclosed herewith.

The detailed disclosure relating to sub-division of face value of equity shares of the Company and Amendments to Memorandum of Association in brief as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as Annexure-III and Annexure-III respectively.

The Board Meeting commenced at 6.30 P.M. and concluded at 8.30 P.M.

alma

Kindly take the same on record.

Yours truly,

Kindly take it on your records

For Sudarshan Pharma Industries Limited

Hemal Mehta Chairman & Ma

Chairman & Managing Directo

Encl: As above



Head office: 301.Aura Biplex, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com

Board Line: + 91-22-42221111 / 42221116 (100 line) CIN: L51496MH2008PLC184997

#### Annexure-I

Calendar of Events for proposed Corporate Action – Split / Sub-division in Nominal Value of Equity Shares of the Company

Event / Activity	Day	Date
Date of Board Resolution authorizing the Director(s) and the Company Secretary to be responsible for the entire Postal Ballot process	30-09-2024	Monday
Cut-Off Date for determining members to whom Postal Ballot Notice will be sent	27-09-2024	Friday
Date of completion of dispatch of Notice by electronic means	04-10-2024	Friday
Remote e-Voting Start Date	05-10-2024	Saturday
Remote e-Voting End Date	03-11-2024	Sunday
Date on which Resolution will be deemed to be passed	03-11-2024	Sunday
Scrutinizer Report	04-11-2024	Monday





Head office: 301.Aura Biplex, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com

Board Line: + 91-22-42221111 / 42221116 (100 line) CIN: L51496MH2008PLC184997

#### Annexure - II

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. no.	Particulars	Particulars				Disclosure				
1	Split ratio	plit ratio			Split / sub-division of 1 (One) Equity Share of the Company having Face Value of Rs.10/- each into 10 (Ten) Equity Shares of Company having Face Value of Re. 1/- each i.e. 10:1					
2	Rationale beh	pehind the Split			In order to enhance the liquidity of Company's Share and to make it more affordable for small investors and also to broaden the company's investor base.					
3	Pre and post share capital, authorized, paid-up and subscribed:									
	Particulars	Pre-Spl	it / Sub	-Divisio		Post-Split/Sub-Division				
		No. of Shares	Face Value (In Rs.)	Total Capita Rs.)	Share (in	No. of Shares	Face Value (In Rs.)	Total Share Capital (in Rs.)		
	Authorised Share Capital	Equity Shares								
		3,50,00,000	10/-	35,00,00,000		35,00,00,000	1/-	35,00,00,000		
	Issued, Subscribed	Equity Shares								
	and paid - up Share- Capital	2,40,65,887	10/-	24,06,58,870		24,06,58,870	1/-	24,06,58,870		
4	Expected time of – Completion					Tentatively within 2 months from the date of Board's Approval				
5	Class of shares which are subdivided			Equity Shares						
6	Number of shares of each class pre and post-split				Equity Shares Pre-split: 2,40,65,887 Equity Shares Post-split: 24,06,58,870 Equity Shares					
7	Number of shareholders who did not get any share in the split and their pre-split shareholding				Not Applicable				no A	



Head office: 301.Aura Biplex, Premium Retail, Premises, 7, S.V.Road Boriwali (west) Mumbai - 400092 E-mail: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com

Board Line: + 91-22-42221111 / 42221116 (100 line) CIN: L51496MH2008PLC184997

#### Annexure-III

Amendments to Memorandum of Association of the Company

#### Alteration of Capital Clause of Memorandum of Association:

The Board of Directors of the Company at its meeting held on Monday, September 30, 2024 subject to approval of the Members, approved alteration of Capital Clause (Clause V) of the Memorandum of Association of the Company as below:

Clause V: The Authorized Share Capital of the Company is Rs. 35,00,00,000 /- (Rupees Thirty Five Crores Only) divided into 35,00,00,000 (Thirty Five Crores only) Equity Shares of Re. 1/- each.